Array Technologies fourth quarter revenue exceeded analysts’ expectations. However, its earnings missed estimates.
The company’s Q4 2021 revenues rose +22% from the year-ago quarter to $219.9 million, beating the consensus estimates of $213.82 million.
Adjusted net loss incurred in the quarter was -$0.06, wider than the expected -$0.03.
Looking ahead, Array projects 2022 revenue in the range of $1.45-$1.75 billion against street expectations of $1.39 billion. The expected revenue growth is roughly 85% at the midpoint, while the legacy Array business is projected to grow by over +40% .
ARRY moved above its 50-day moving average on April 30, 2026 date and that indicates a change from a downward trend to an upward trend. In of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 02, 2026. You may want to consider a long position or call options on ARRY as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on May 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where ARRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where ARRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARRY broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ARRY's P/B Ratio (15.432) is slightly higher than the industry average of (5.258). P/E Ratio (56.911) is within average values for comparable stocks, (129.210). Projected Growth (PEG Ratio) (0.936) is also within normal values, averaging (1.919). ARRY's Dividend Yield (0.000) is considerably lower than the industry average of (0.059). P/S Ratio (1.025) is also within normal values, averaging (15.373).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceutical drugs
Industry AlternativePowerGeneration